November 2020 Issue Table Of Contents

From The Editor

• Amidst COVID-19 There Is Much To Be Thankful

Feature Articles

• The Making Of A Pharma CEO

Capitol Perspectives

• Implementation Of MFN, Importation, And Other Mischief In 2020

CEO Corner

• Key Learnings While Forging A Partnership In Unprecedented Times
• The Role Of Failure In Innovation

Companies To Watch

• Ridgeback Biotherapeutics

From Policy to Execution

• Public Health’s Vexing Past And Confounding Near-Time Future

Industry Research

• Top 5 Challenges In Finding Rare Disease Patients

Inside The Industry

• The Power That Industry Lexicon Has To Support Change
• Life Sciences Dealmaking In The Time Of COVID-19
• The Road To Commercialization: Small Company Considerations
• Pets, Perseverance, and Manufacturing Facility Bring Biotech Success
• Paragraph IV Patent Challenges During COVID-19: What’s Next?

Leadership Lessons

• Coaching Through Crisis

Ask The Board

• What Was Your Biggest Business Learning From The First Half Of 2020 And Why?
• What Is Your Biggest Concern Regarding Biopharma’s Reputation With The American People If We Do Not Have A COVID-19 Vaccine By The End Of 2020?
• What — If Any — “Silver Linings” Have You Observed Take Place At Your Company Resulting From The Chaos Caused By COVID-19?